Cargando…
Biosimilar monoclonal antibodies in China: A patent review
Biosimilars play an important role in reducing the burden on patients and increasing the market competition. Biosimilar monoclonal antibodies are currently one of the hotspots of research and development in China with policies support. With the continuous improvement of policies, the enthusiasm for...
Autores principales: | Liu, Jia-Wei, Yang, Yu-Huan, Wu, Nan, Wei, Ji-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342192/ https://www.ncbi.nlm.nih.gov/pubmed/35758066 http://dx.doi.org/10.1080/21655979.2022.2090206 |
Ejemplares similares
-
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020) -
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019) -
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019) -
Expert perspectives on biosimilar monoclonal antibodies in breast cancer
por: Cortés, J., et al.
Publicado: (2014) -
Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)